First-in-Human Study of Abbv-621, a TRAIL Receptor Agonist Fusion Protein, in Patients (Pts) with Relapsed/Refractory (RR) Acute Myeloid Leukemia (AML) and Diffuse Large B-Cell Lymphoma (DLBCL)Maja J.A. de Jonge, Víctor Moreno, Sudhir Penugonda et al.|Blood|2019Cited by 11
AML-058: First-In-Human Study of a Trail Receptor Agonist Fusion Protein, Eftozanermin Alfa, in Patients with Relapsed/Refractory Acute Myeloid Leukemia and Diffuse Large B-Cell LymphomaMojca Jongen‐Lavrencic, Daniel Morillo, Junichiro Yuda et al.|Clinical Lymphoma Myeloma & Leukemia|2020Cited by 2